The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Clinical trial NCT07069725 · COMPLETED
Trial details
- NCT number
- NCT07069725
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-26
- Primary completion
- 2026-07-02
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.